Hydrazine Sulfate CAS 10034-93-2 Hydrazine sulfate salt

Payment Terms: T/T,L/C,WU
Trade on HiSupplier, Worry Free Guarantee
Trading safety, secure your money, lower the risk, protect both buyers and suppliers
HiSupplier is a Chinese multinational company in U.S, it helps to coordination and order landing.
More ›
  • Product Details
  • Company Profile
  • Product Reviews
Basic Info.
  • Brand Name: MOSINTER 
  • CAS No.: 10034-93-2 
  • Melting Point: 254 °C(lit.) 
  • Density: 1,37 g/cm3 
  • Soluble: 30 g/L (20 ºC) 
  • Stability: Stable. Incompatible with nitrites, strong oxidizing agents. 
  • Place of Origin: Shandong  
  • Min.Order: 1 Ton
  • Means of Transport: Land, Ocean, Air
Supply Capacity
  • Production Capacity: 2000 Ton/Year
  • Packing:According to the request of customer
  • Delivery Date: within 7 days

 Hydrazine Sulfate(CAS: 10034-93-2)




Molecular weight


Molecular formula



Crystals or white powder

Dry agent content, ≥   %


The mass fraction of the water, ≤   %


Insoluble in water, ≤ %


Melting, ℃


Hydrazine sulfate is the salt of hydrazine and sulfuric acid. Known by the trade name Sehydrin, it is a chemical compound that has been used as analternative medical treatment for the loss of appetite (anorexia) and weight loss (cachexia) which is often associated with cancer. Hydrazine sulfate has never been approved in theUSas safe and effective in treating any medical condition, although it is marketed as a dietary supplement. It is also sold over the Internet by websites that promote its use as a cancer therapy. The active ingredient is hydrazine, and the sulfate component is present to aid in formulation.

The main proponent of hydrazine sulfate as an anti-cancer agent is aU.S.physician named Joseph Gold, who developed the treatment in the mid-1970s. The use of hydrazine sulfate as a cancer remedy was popularized by the magazine Penthouse in the mid-1990s, when Kathy Keeton, wife and business partner of the magazine's publisher Bob Guccione, used it in an attempt to treat her metastatic breast cancer.[7] Nutritionist Gary Null wrote three of the articles about alternative cancer treatments, including one entitled "The Great Cancer Fraud." Keeton (until her death in 1997) and other supporters of hydrazine sulfate treatment accused the U.S. National Cancer Institute (NCI) of deliberately hiding the beneficial effects of the compound, and threatened to launch a class action lawsuit. The NCI denied the claims, and says that there is little to no evidence that hydrazine sulfate has any beneficial effects whatsoever. The position of the NCI was supported by an inquiry held by the General Accounting Office.

A review of the clinical research concluded that hydrazine sulfate has never been shown to act as an anticancer agent; patients do not experience remissions or regressions of their cancer, and patients do not live longer than non-treated patients. Some academic reviews of alternative cancer treatments have described the compound as a "disproved and ineffective treatment for cancer".

Hydrazine sulfate also has a variety of uses in the chemical industry.

Industrial uses

Hydrazine sulfate also has a variety of uses in industrial chemistry, including as a chemical intermediate, as a catalyst in making fibers out of acetate, as a fungicide, antiseptic, in the analysis and synthesis of minerals and testing for arsenic in metals.

Clinical trials

Joseph Gold, the developer and principal proponent of hydrazine sulfate, has published several papers arguing that the compound is an effective cancer treatment. These data have been questioned by the American Cancer Society and other investigators have been unable to repeat or confirm these results. Gold is reported not to trust the motives or results of other investigators, with CNN quoting him as stating that "they've been out to get hydrazine sulfate, and I don't know why".

In response to these results, an uncontrolled clinical trial was carried out at the Petrov Research Institute of Oncology in St. Petersburg over a period of 17 years, and a controlled trial was carried out at the Harbor-UCLA Medical Center in California over period of 10 years, respectively. The Russian trial reported complete tumor regression in about 1% of cases, a partial response in about 3% of cases and some subjective improvement of symptoms in about half of the patients. The National Cancer Institute analysis of this trial notes that interpretation of these data is difficult, due to the absence of controls, the lack of information on prior treatment and the study's reliance on subjective assessments of symptoms (i.e.asking patients if the drug had made them feel any better). Overall, the trials in California saw no statistically significant effect on survival from hydrazine sulfate treatment, but noted increased calorie intake in treated patients versus controls.The authors also performed a post-hoc analysis on one or more subgroups of these patients, which they reported as suggesting a beneficial effect from treatment. The design and interpretation of this trial, and in particular the validity of this subgroup analysis, was criticized in detail in an editorial in the Journal of Clinical Oncology.

Later randomized controlled trials trials failed to find any improvement in survival,  For example, in a trial of the treatment of advanced lung cancer, with either cisplatin andvinblastine or these drugs plus hydrazine sulfate, saw complete tumor regression in 4% of the hydrazine group, versus 3% in the control group, and tumor progression in 36% of the hydrazine group, versus 30% of the control group; however, none of these differences were statistically significant. Some trials even found both significantly decreased survival and significantly poorer quality of life in those patients receiving hydrazine sulfate. These consistently negative results have resulted in hydrazine sulfate being described as a "disproven cancer therapy" in a recent medical review. Similarly, other reviews have concluded that there is "strong evidence" against the use of hydrazine sulfate to treat anorexia or weight loss in cancer patients.

Send message to this supplier
Mr. Fedor
Tel: +86-574-89212210
Mobile: +86-18989305995
Enter between 20 to 3,000 chatacters.
Contact Method
Guangbo Center Office 2001, YinXianDaDao 1357, Ningbo, Zhejiang, China (Mainland) / 315100
Fax: +86-574-89212215
Didn't find what you're looking for? Post Buying Lead or contact our customer service specialist for help!
Buyer Help Center